Comparing two prostate cancer medicines
This study looks at how well two medicines, enzalutamide and darolutamide, work for men with prostate cancer that has spread (metastatic) and is still sensitive to hormone therapy. It will help doctors understand which medicine might be better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man with prostate cancer that has spread to other parts of the body.
- Your prostate cancer is castration sensitive, meaning it hasn't stopped responding to hormone therapy that lowers testosterone.
- Your treatment plan includes one of the study medicines (enzalutamide or darolutamide) combined with androgen deprivation therapy (ADT) as your first treatment for metastatic cancer.
- You started your current prostate cancer treatment on or after August 1, 2022.
- You haven't had chemotherapy with docetaxel or any other experimental drug for your prostate cancer before this treatment.
- You don't have other cancers, except for non-melanoma skin cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Metastatic Castration Sensitive Prostate Cancer (mCSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.